Taken together, these results show that IL-1β neutralization prevents the development of incipient KRASMUT LUAD in humans, that KRASMUT human cancers contain elevated IL-1β levels, and that mouse KrasMUT cancers are specifically dependent on host IL-1β signaling, supporting the hypothesis of a selective non-oncogene addiction of KRASMUT cancers to IL-1β. The gene discussed is IL1B; the disease is cancer.